Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

6.100 +0.050 (+0.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
ARS Pharmaceuticals (NASDAQ:SPRY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment ↗
Via Chartmill
News headline image
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY
San Diego, California--(Newsfile Corp. - August 13, 2026) - Robbins LLP reminds shareholders that a securities class action has been... 
Via Newsfile
Topics Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY
From DJS LAW GROUP
Via Business Wire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Shareholder Notice: Robbins LLP Informs Investors of the ARS Pharmaceuticals Inc. Class Action
From Robbins LLP
Via Business Wire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces CEO Succession
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
ARS Pharmaceuticals Provides Commercial and Financial Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma (SPRY) Q1 2026 Earnings Transcript ↗
ARS Pharma (SPRY) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
ARS Pharma (SPRY) Q4 2025 Earnings Transcript ↗
ARS Pharma (SPRY) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
ARS Pharmaceuticals Q1 Earnings Call Highlights ↗
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.